Company Focus
Novo Nordisk
Latest Novo Nordisk News
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Related News
Insights
Company Spotlight
Acadia Pharmaceuticals (Nasdaq: ACAD) is a leading pharmaceutical company with a focus on bringing life-changing therapies to patients suffering from CNS diseases.
Latest News & Features of interest to Novo Nordisk
Biotechnology
Dizal has announced the latest data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, in B-cell non-Hodgkin lymphoma (B-NHL). 9 December 2024
Biotechnology
AbbVie has announced updated results from the Phase Ib/II EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide and rituximab (R2) in relapsed or refractory (R/R) follicular lymphoma (FL). 9 December 2024
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Pharmaceutical
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. 9 December 2024
Pharmaceutical
Chinese biotech Abbisko Therapeutics has shared Phase II trial results for its oral CSF-1R inhibitor pimicotinib at the 66th ASH annual conference in San Diego. 9 December 2024
Biotechnology
Johnson & Johnson has unveiled positive early data for its multiple myeloma treatment Tecvayli (teclistamab) from two clinical studies focused on people with newly diagnosed multiple myeloma. 9 December 2024
Pharmaceutical
Sanofi has unveiled promising Phase III results for rilzabrutinib, its oral Bruton’s tyrosine kinase (BTK) inhibitor, at this year’s American Society of Hematology (ASH) meeting. 9 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). 9 December 2024
Biotechnology
Deal-making featured strongly among last week’s news, first with PCT Therapeutics inking an up to 2.9 billion collaboration with Swiss pharma giant Novartis on its PTC518 program for Huntington’s disease. Dutch firm Merus entered a licensing deal with Partner Therapeutics on the development of zenocutuzumab. Japan’s Takeda announced a deal with Keros Therapeutics for the development of myelofibrosis candidate elritercept. Also of note, Merus scored a first with US Food and Drug Administration (FDA) approval for its Bizengri for lung cancer. 8 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Latest In Brief for Novo Nordisk
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Related Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
7 December 2024
3 December 2024
28 November 2024
26 November 2024
21 November 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze